All News
Filter News
Found 130 articles
-
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
5/31/2018
Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the appointment of Jeff Conroy and Jeff Hargroves to its Board of Directors
-
Cingulate Therapeutics Appoints Laurie Myers, PhD, MBA as Chief Operating Officer
4/2/2018
Dr. Myers currently serves as a founding member of the Cingulate Therapeutics Board of Directors.
-
Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
1/15/2018
Overall, researchers found that CTX-1301 delivered consistent tri-modal release of the dexmethylphenidate hydrochloride.
-
Cingulate Therapeutics Appoints Experienced Lead Investigator Matthew Brams, MD as CMO
1/9/2018
Dr. Brams is a Co-Founder of Cingulate Therapeutics and currently serves as a member of the Board of Directors.
-
RSNA Release: Brain's Appetite Regulator Disrupted in Obese Teens
11/30/2017
The study at the University of Sao Paulo in Brazil included 59 obese adolescents between the ages of 11 and 18 and 61 healthy control adolescents matched for gender, age, socio-economical classification and education level.
-
RSNA Release: Smartphone Addiction Creates Imbalance in Brain
11/30/2017
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet, according to a study presented today at the annual meeting of the RSNA.
-
RSNA Study: MRI Uncovers Brain Abnormalities in People with Depression and Anxiety
11/20/2017
Researchers using MRI have discovered a common pattern of structural abnormalities in the brains of people with depression and social anxiety, according to a study being presented next week at the annual meeting of the RSNA.
-
Cingulate Therapeutics to Present in Vivo Pharmacokinetic Data Demonstrating Consistent Tri-Phasic Release Profile of Lead Compound at the AAPS Annual Meeting
11/15/2017
The study evaluated CTX-1301, Cingulate's proprietary, first-line stimulant medication for the treatment of ADHD, utilizing an innovative, proprietary timed release technology OralogiK developed by CTx's partner BDD.
-
Cingulate Partners With Camargo Pharmaceutical Services For Development Programs
8/8/2017
-
Imaging Study Expands Upon Previous Findings That Cefaly Device Is Effective In Blocking Migraine Pain
7/25/2017
-
Alzheimer's Association Launches $20 Million Lifestyle Intervention Trial In The U.S. To Prevent Cognitive Decline
7/19/2017
-
Cingulate Appoints Strategic Finance Veteran Louis G. Van Horn As Chief Financial Officer
7/10/2017
-
Cingulate Moves HQ To Aratana's Old Space To Accommodate Growth
6/15/2017
-
Brainsway Announces Positive Final Results Of Its Deep TMS Multicenter Study In Obsessive Compulsive Disorder (OCD) Patients
6/12/2017
-
Cingulate Initiates First Human Clinical Trial
5/31/2017
-
NYU Langone Medical Center Release: Chronic Pain Amplifies The Brain's Reaction To New Injuries
5/22/2017
-
Revealed: The Brain's Generosity Center, Oxford University Study
8/17/2016
-
Why Obese Women Have An Uncontrollable Urge To Eat, University of Texas Southwestern Medical Center Study Reveals
7/25/2016
-
Donald Trump Appeals To The Brains Of Voters—Will It Win Him The Election?
7/25/2016
-
What Social Media Does To A Teenager's Brain, UCLA Study
6/3/2016